



# Effectiveness of Suprascapular Nerve Block in the Treatment of Hemiplegic Shoulder Pain: A Systematic Review and Meta-Analysis

#### Yajing Hou<sup>1,2</sup>, Yong Wang<sup>2</sup>, Xiaojing Sun<sup>3</sup>, Yake Lou<sup>4</sup>, Ying Yu<sup>5</sup> and Tong Zhang<sup>1\*</sup>

<sup>1</sup> School of Rehabilitation Medicine, Capital Medical University, Department of Neurological Rehabilitation, Beijing Bo'ai Hospital, China Rehabilitation Research Center, Lab of Brain Injury Repair and Rehabilitation, China Rehabilitation Science Institute, Beijing, China, <sup>2</sup> Rehabilitation Medicine Center, Fuxing Hospital, Capital Medical University, Beijing, China, <sup>3</sup> Capital Medical University, Beijing Rehabilitation Hospital, Shijingshan, Beijing, China, <sup>4</sup> Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China, <sup>5</sup> Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

**Purpose:** We aimed to investigate the effectiveness of suprascapular nerve block (SSNB) in patients with hemiplegic shoulder pain (HSP).

**Background:** SSNB is widely used in various shoulder pains, but whether it is effective in HSP remains unknown.

#### **OPEN ACCESS**

#### Edited by:

Giorgio Scivoletto, Santa Lucia Foundation (IRCCS), Italy

#### Reviewed by:

Murat Mert, Yeni Yüzyil University, Turkey Marcello Romano, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Italy

> \*Correspondence: Tong Zhang tom611@126.com

#### Specialty section:

This article was submitted to Neurorehabilitation, a section of the journal Frontiers in Neurology

Received: 11 June 2021 Accepted: 01 September 2021 Published: 05 October 2021

#### Citation:

Hou Y, Wang Y, Sun X, Lou Y, Yu Y and Zhang T (2021) Effectiveness of Suprascapular Nerve Block in the Treatment of Hemiplegic Shoulder Pain: A Systematic Review and Meta-Analysis. Front. Neurol. 12:723664. doi: 10.3389/fneur.2021.723664 **Methods:** PubMed, Cochrane Library, and Embase databases were searched to identify potential citations. Randomized controlled trials meeting the eligible criteria were included in our analysis. The primary endpoint was Visual Analog Scale (VAS) with a maximum value of 100 and a minimum value of 0. Secondary endpoints were passive range of motion (PROM) that pain starts, and the PROM mainly included abduction, flexion, and external rotation. In addition, the upper extremity Fugl-Meyer assessment (FMA) was also included in our secondary endpoints.

**Results:** Eight studies with 281 patients were included in our analysis. For VAS, there was no obvious difference between SSNB group and control group regardless of the follow-up period (<4 weeks or  $\geq$ 4 weeks), which were -6.62 (-15.76, 2.53; p = 0.16) and 1.78 (-16.18, 19.74; p = 0.85). For shoulder function, the PROM of abduction, flexion, and external rotation was similar between groups. However, motor function indicator FMA is lower in SSNB control than that in control group, with a mean difference (and 95% CI) of -2.59 (-4.52, -0.66; p = 0.008).

Conclusion: SSNB is an effective way for HSP patients.

Systematic Review Registration: Registration ID: CRD42021252429.

Keywords: suprascapular nerve block, hemiplegic shoulder pain, meta-analysis, nerve block, shoulder pain, systematic review

## INTRODUCTION

Hemiplegic shoulder pain (HSP), as a very common poststroke complication, often occurs within a week after stroke (1). According to different studies, the incidence of HSP ranges from 16% to 84% in poststroke patients (2, 3). HSP patients may have nocturnal pain, but the most obvious pain is during passive external rotation and shoulder abduction (4), which limits the motion of the

1

shoulder. In turn, the limited shoulder aggravates the HSP (5). As far as we know, the etiology of HSP is complex and varied, mainly including soft tissue lesions, muscle tone changes, and altered central nervous system phenomena (6). Currently, suprascapular nerve block (SSNB), botulinum toxin A, and intraarticular steroid injection are used in clinical practice, the optimal treatment for HSP still unknown (5).

About 70% of the shoulder joint sensorial fibers run through the suprascapular nerve (SSN) (7), so the blockage or damage of SSN may contribute to alleviating HSP. In

recent years, some studies found that SSNB can reduce the pain intensity of HSP, thus improving the motion of shoulder joint (8, 9), but some other studies drew a negative conclusion that there is no difference in pain relief in a 6week follow-up of SSNB for HSP (10); a study even found that SSNB is inferior to other treatments (11). Given the controversial effect of SSNB on HSP and the small samples in each study, it is important for us to perform a metaanalysis to investigate the real effects of SSNB in the treatment of HSP.




TABLE 1 | Baseline characteristics of included studies.

Study name	Journal	Total	SSNB	Control	Interventio	on Way of control	Agents of SSNB	Agents of control
Boonsong et al. (16)	J Med Assoc Thai	10	5	5	SSNB	Ultrasound Treatment	Lidocaine	Ultrasound Power
Adey-Wakeling et al. (8)	Stroke	64	32	32	SSNB	Placebo	Methylprednisolone +Bupivacaine Hydrochloride	Normal Saline
Kim and Kim (15)	Brain Neurorehabil	24	12	12	SSNB	Intra-Articular Hyaluronic Acid Injection	Lidocaine	Hyaluronic Acid
Sencan et al. (9)	Neurological Sciences	30	20	10	SSNB	Intraarticular Shoulder Injection	Bupivacaine	Methylprednisolone Acetate
Alanbay et al. (11)	Pain Physician	30	15	15	SSNB	Suprascapular nerve pulsed radiofrequency	Lidocaine	Pulsed Radiofrequency
Kasapoglu-Aksoy et al. (10)	Neurological Sciences	57	27	30	SSNB	Botulinum Toxin-A Injection	Lidocaine+Triamcinolone Hexacetonide	Botulinum Toxin-A
Terleme, et al. (14)	Neurological Sciences	30	20	10	SSNB	Placebo	Lidocaine	Lidocaine
Tubay et al. (13)	Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi	36	18	18	SSNB	Glenohumeral Joint Injection	Prilocaine+Triamcinolone Acetonide	Prilocaine+Triamcinolon Acetonide

## **METHODS**

#### Search Strategy

The keywords "hemiplegia," "monoplegia," "paresis," "spastic paresis," "cerebrovascular accident," "stroke," "basal ganglia hemorrhage," "brain ischemia," "brain infarction," "intracranial hemorrhage," "subarachnoid hemorrhage," "post-stroke," "shoulder pain," "suprascapular nerve block," "blockade," and "suprascapular fossa" were used to search Pubmed, Embase, and Cochrane database to identify potential randomized controlled trials (RCTs) until May 2, 2021 (further details are available in the **Supplementary Material**). Only citations whose titles and abstracts are published in English are potential for eligibility.

#### **Eligibility Criteria**

Studies with the following criteria could be eligible for inclusion:

- 1: RCTs.
- 2: The intervention group is conducted with SSNB and the control group with placebo or active control.
- 3: At least one interesting outcome reported.
- 4: Sample size is not less than 10.

## **Exclusion Criteria**

- 1: Animal experiments.
- 2: Retrospective studies.
- 3: Cohort studies.
- 4: Studies with no randomization.

## **Data Extraction and Quality Assessment**

Two authors (YH and YW) independently screened the searched citations to find out eligible citations. Disagreement between YH and YW was resolved by another author (TZ). Any potential citations that were uncertain to meet the inclusion

criteria would be evaluated further by reading the full text. After screening, YH and YW continued to extract data in the inclusion reference. Baseline characteristics, inclusion criteria, exclusion criteria, intervention measure, outcome measure, and results would be extracted independently by YH and YW. Quality assessment of included references was performed by YL and YY according to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0), and the main evaluation criteria included random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other biases.

#### Outcomes

The primary endpoint for the present meta-analysis was Visual Analog Scale (VAS) with a maximum value of 100 and a minimum value of 0. Secondary endpoints were passive range of motion (PROM) that pain starts, and the PROM mainly included abduction, flexion, and external rotation. In addition, the upper extremity Fugl-Meyer assessment (FMA) was also included in our secondary endpoints.

#### **Statistical Analysis**

All the statistical analyses were conducted using Review Manager (RevMan) version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) and Stata 15.1 (StataCorp, College Station, TX, USA) software. The study was performed in reference to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement and was registered in the PROSPERO database (No.: CRD42021252429) (12). The mean difference and 95% confidence interval (CI) were calculated by inverse variance analysis. Considering the different control

	5	SSNB		С	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 Active control									
Boonsong,2009	30.2	19.3	5	59.4	7.5	5	11.5%	-29.20 [-47.35, -11.05]	
Kasapoglu-Aksoy,2020	41.3	12.5	27	40	9.8	30	19.4%	1.30 [-4.58, 7.18]	+
Kim,2014	47.5	13.6	12	41.7	15.9	12	15.6%	5.80 [-6.04, 17.64]	
Sencan,2019	30	16.8	20	26.3	25.8	10	11.8%	3.70 [-13.90, 21.30]	
Tubay,2012	36.7	18.5	18	35	18.6	18	15.4%	1.70 [-10.42, 13.82]	
Subtotal (95% CI)			82			75	73.8%	-1.64 [-10.67, 7.39]	<b>+</b>
Heterogeneity: Tau <sup>2</sup> = 63	.77; Chi <sup>2</sup>	= 11.2	8, df =	4 (P = 0	.02); I <sup>2</sup>	= 65%			
Test for overall effect: Z =									
1.1.2 Placebo control									
Terlemez,2020	34	15.4	20	55	24	10	12.6%	-21.00 [-37.33, -4.67]	
Wakeling,2013	29.8	29	32	47.9	31.4	32	13.6%	-18.10 [-32.91, -3.29]	
Subtotal (95% CI)			52			42	26.2%	-19.41 [-30.38, -8.44]	◆
Heterogeneity: Tau <sup>2</sup> = 0.0	)0; Chi <sup>2</sup> =	0.07,	df = 1 (	P = 0.80	));  ² =	0%			
Test for overall effect: Z =	3.47 (P	= 0.00	05)						
Total (95% CI)			134			117	100.0%	-6.62 [-15.76, 2.53]	•
Heterogeneity: Tau <sup>2</sup> = 10	3.08; Ch	i² = 21	94, df=	= 6 (P =	0.001)	; l² = 73	3%		-100 -50 0 50 100
Test for overall effect: Z =	: 1.42 (P	= 0.16	)						Favours [SSNB] Favours [Control]
Test for subaroup differe VAS ≥4 week		ni² = 6.1	01. df=	1 (P = (	).01). P	²= 83.4	1%		
	5	SSNB	Total		ontrol	Tetal	Mainht	Mean Difference	Mean Difference
Study or Subgroup	Mean	50	Total	Mean	50	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.2.1 Active control	60	10	15	20	20	15	10.60	24 00 (22 20 45 00)	
Alanbay,2020	62 10 9	12	15	28	20		12.6%	34.00 [22.20, 45.80]	
Alanbay,2020 Boonsong,2009	19.8	15.4	5	50	2.6	5	12.4%	-30.20 [-43.89, -16.51]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020	19.8 67.5	15.4 10	5 27	50 33.6	2.6 12.3	5 30	12.4% 13.2%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70]	 
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014	19.8 67.5 31.7	15.4 10 15.9	5 27 12	50 33.6 30	2.6 12.3 10.4	5 30 12	12.4% 13.2% 12.8%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019	19.8 67.5 31.7 43	15.4 10 15.9 33.8	5 27 12 20	50 33.6 30 38.7	2.6 12.3 10.4 17.2	5 30 12 10	12.4% 13.2% 12.8% 11.8%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012	19.8 67.5 31.7 43	15.4 10 15.9	5 27 12 20 18	50 33.6 30 38.7	2.6 12.3 10.4	5 30 12 10 18	12.4% 13.2% 12.8% 11.8% 12.8%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 <b>Subtotal (95% CI)</b>	19.8 67.5 31.7 43 41.9	15.4 10 15.9 33.8 15.3	5 27 12 20 18 <b>97</b>	50 33.6 30 38.7 40.3	2.6 12.3 10.4 17.2 17.1	5 30 12 10 18 <b>90</b>	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> %	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012	19.8 67.5 31.7 43 41.9 '3.13; Chi	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10	5 27 12 20 18 <b>97</b> 3.78, dt	50 33.6 30 38.7 40.3	2.6 12.3 10.4 17.2 17.1	5 30 12 10 18 <b>90</b>	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> %	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57	19.8 67.5 31.7 43 41.9 '3.13; Chi	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10	5 27 12 20 18 <b>97</b> 3.78, dt	50 33.6 30 38.7 40.3	2.6 12.3 10.4 17.2 17.1	5 30 12 10 18 <b>90</b>	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> %	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = 1.2.2 Placebo control	19.8 67.5 31.7 43 41.9 3.13; Chi - 0.78 (P =	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43	5 27 12 20 18 97 3.78, dt	50 33.6 30 38.7 40.3	2.6 12.3 10.4 17.2 17.1	5 30 12 10 18 <b>90</b> 001); F	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> % = 95%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b>	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = 1.2.2 Placebo control Terlemez,2020	19.8 67.5 31.7 43 41.9 3.13; Chi 0.78 (P = 39	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43	5 27 12 20 18 97 3.78, df	50 33.6 30 38.7 40.3 f= 5 (P	2.6 12.3 10.4 17.2 17.1 < 0.000	5 30 12 10 18 <b>90</b> 001); F	12.4% 13.2% 12.8% 12.8% 75.5% = 95%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b>	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = 1.2.2 Placebo control	19.8 67.5 31.7 43 41.9 3.13; Chi 0.78 (P = 39	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43	5 27 12 20 18 97 3.78, dt	50 33.6 30 38.7 40.3 f= 5 (P	2.6 12.3 10.4 17.2 17.1	5 30 12 10 18 <b>90</b> 001); F	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> % = 95% 12.2%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b>	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = <b>1.2.2 Placebo control</b> Terlemez,2020 Wakeling,2013 Subtotal (95% CI)	19.8 67.5 31.7 43 41.9 3.13; Chi = 0.78 (P 39 28.1	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43 18 28.6	5 27 12 20 18 97 3.78, dt ) 20 32 32 52	50 33.6 30 38.7 40.3 7= 5 (P 55 46.2	2.6 12.3 10.4 17.2 17.1 < 0.000 20.9 32.1	5 30 12 10 18 <b>90</b> 001); F 10 32 42	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> % = 95% 12.2%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b> -16.00 [-31.17, -0.83] -18.10 [-33.00, -3.20]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = 1.2.2 Placebo control Terlemez,2020 Wakeling,2013	19.8 67.5 31.7 43 41.9 3.13; Chi 5.0.78 (P 39 28.1 00; Chi <sup>z</sup> =	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43 18 28.6 : 0.04,	5 27 12 20 18 97 3.78, dt ) 20 32 52 52 df = 1 (	50 33.6 30 38.7 40.3 7= 5 (P 55 46.2	2.6 12.3 10.4 17.2 17.1 < 0.000 20.9 32.1	5 30 12 10 18 <b>90</b> 001); F 10 32 42	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> % = 95% 12.2%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b> -16.00 [-31.17, -0.83] -18.10 [-33.00, -3.20]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = <b>1.2.2 Placebo control</b> Terlemez,2020 Wakeling,2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.0	19.8 67.5 31.7 43 41.9 3.13; Chi 5.0.78 (P 39 28.1 00; Chi <sup>z</sup> =	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43 18 28.6 : 0.04,	5 27 12 20 18 97 3.78, dt ) 20 32 52 52 df = 1 (	50 33.6 30 38.7 40.3 7= 5 (P 55 46.2	2.6 12.3 10.4 17.2 17.1 < 0.000 20.9 32.1	5 30 12 10 18 90 001); ₣ 10 32 42 0%	12.4% 13.2% 12.8% 11.8% 12.8% <b>75.5</b> % = 95% 12.2%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-9.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b> -16.00 [-31.17, -0.83] -18.10 [-33.00, -3.20]	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = <b>1.2.2 Placebo control</b> Terlemez,2020 Wakeling,2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z =	19.8 67.5 31.7 43 41.9 '3.13; Chi = 0.78 (P = 39 28.1 00; Chi <sup>2</sup> = = 3.15 (P =	15.4 10 15.9 33.8 15.3 i <sup>2</sup> = 10 = 0.43 18 28.6 : 0.04, = 0.00	5 27 12 20 18 97 3.78, dt ) 20 32 52 df = 1 ( 2) 149	50 33.6 30 38.7 40.3 (= 5 (P 55 46.2 P = 0.88	2.6 12.3 10.4 17.2 17.1 < 0.000 20.9 32.1 5);   <sup>2</sup> = 1	5 30 12 10 18 90 001); F 10 32 42 0% 132	12.4% 13.2% 12.8% 11.8% 12.8% 75.5% = 95% 12.2% 24.5%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-8.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b> -16.00 [-31.17, -0.83] -18.10 [-33.00, -3.20] - <b>17.07 [-27.70, -6.44]</b>	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = 1.2.2 Placebo control Terlemez,2020 Wakeling,2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z = Total (95% CI)	19.8 67.5 31.7 43 41.9 3.13; Chi = 0.78 (P = 39 28.1 00; Chi <sup>2</sup> = = 3.15 (P =	15.4 10 15.9 33.8 15.3 $i^{2} = 10$ = 0.43 18 28.6 : 0.04, = 0.00 $i^{2} = 14$	5 27 12 20 18 97 3.78, dt ) 20 32 52 df = 1 ( 2) 149 0.57, dt	50 33.6 30 38.7 40.3 (= 5 (P 55 46.2 P = 0.88	2.6 12.3 10.4 17.2 17.1 < 0.000 20.9 32.1 5);   <sup>2</sup> = 1	5 30 12 10 18 90 001); F 10 32 42 0% 132	12.4% 13.2% 12.8% 11.8% 12.8% 75.5% = 95% 12.2% 24.5%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-8.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b> -16.00 [-31.17, -0.83] -18.10 [-33.00, -3.20] - <b>17.07 [-27.70, -6.44]</b>	
Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 57 Test for overall effect: Z = <b>1.2.2 Placebo control</b> Terlemez,2020 Wakeling,2013 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z = Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 62	19.8 67.5 31.7 43 41.9 3.13; Chi = 0.78 (P = 	15.4 10 15.9 33.8 15.3 1 <sup>2</sup> = 10 = 0.43 28.6 : 0.04, = 0.00 i <sup>2</sup> = 14 = 0.85	5 27 12 20 18 97 3.78, dt ) 20 32 52 df = 1 ( 2) 149 0.57, dt	50 33.6 30 38.7 40.3 7 = 5 (P - 55 46.2 P = 0.85 7 = 7 (P -	2.6 12.3 10.4 17.2 17.1 < 0.000 20.9 32.1 5); I <sup>2</sup> = 1 < 0.000	5 30 12 10 18 90 001); F 10 32 42 0% 132 0%	12.4% 13.2% 12.8% 12.8% 75.5% = 95% 12.2% 12.2% 24.5% = 95%	-30.20 [-43.89, -16.51] 33.90 [28.10, 39.70] 1.70 [-8.05, 12.45] 4.30 [-13.95, 22.55] 1.60 [-9.00, 12.20] <b>7.91 [-11.89, 27.70]</b> -16.00 [-31.17, -0.83] -18.10 [-33.00, -3.20] - <b>17.07 [-27.70, -6.44]</b>	-100 -50 0 50 100 Favours [SSNB] Favours [Control]

groups, we used the random-effects model to deal with possible heterogeneity. Sensitivity analysis was performed by sequentially omitting one trial, and publication bias was evaluated by the visual funnel plot. Subgroup analyses based on different controls were performed to detect the real effects of SSNB.

## RESULTS

#### **Study Selection**

We identified 194 citations in total by searching PubMed, Embase, and Cochrane database using our keywords. After removing 53 duplicates, we further excluded 128 citations by browsing titles and abstracts, and then we evaluated the remaining 13 citations with full text. Of the 13 fulltext articles, five articles are excluded because of protocol, same study, no randomization, and no control. Finally, eight studies with 281 patients were included in our meta-analysis (flowchart in **Figure 1** and search strategy details in the **Supplementary Material**) (8–11, 13–16).

#### **Characteristics of Eligible Studies**

Of the included 281 patients, 149 (53.0%) were assigned to the SSNB group, and 135 (47.0%) were assigned to the control group. The follow-up period ranged from 4 to 12 wk. The largest RCT owns a sample number of 60 and the smallest of 10. The treatment for control group consists of two placebo

	5	SSNB		С	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
2.1.1 Active control									
Boonsong,2009	133	32.3	5	101	12.5	5	5.4%	32.00 [1.64, 62.36]	
Kasapoglu-Aksoy,2020	78.7	17.5	27	77.4	12.3	30	45.8%	1.30 [-6.63, 9.23]	-
Kim,2014	157.5	18.3	12	151.3	26.7	12	13.6%	6.20 [-12.11, 24.51]	
Sencan,2019	129	24.3	20	135	25	10	13.0%	-6.00 [-24.80, 12.80]	
Tubay,2012	124.4	21.9	18	125.8	19.6	18	22.3%	-1.40 [-14.98, 12.18]	
Subtotal (95% CI)			82			75	100.0%	2.08 [-5.18, 9.33]	<b>*</b>
Heterogeneity: Tau <sup>2</sup> = 13	.52: Chi <sup>2</sup>	= 4.91	df = 4	(P = 0.3)	30); l <sup>z</sup> =	19%			
Test for overall effect: Z =	•				/1 -				
2.1.2 Placebo control									
			0			0		Not estimable	
Subtotal (95% Cl)	aabla		0			0		Notestinable	
Heterogeneity: Not appli		blo							
Test for overall effect: No	it applica	bie							
Total (95% CI)			82			75	100.0%	2.08 [-5.18, 9.33]	<b>+</b>
Heterogeneity: Tau <sup>2</sup> = 13	.52: Chi <sup>≥</sup>	= 4.91	. df = 4	(P = 0.3)	30): l² =	19%		•	
Test for overall effect: Z =					// -				-100 -50 0 50 100
Test for subaroup differe									Hazards [SSNB] Hazards [Control]
Abduction H				eks					
noude eron i			"0						
	s	SSNB		с	ontrol			Mean Difference	Mean Difference
Study or Subgroup	s	SSNB		с		Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control	S Mean	SSNB SD	Total	C Mean	SD			IV, Random, 95% Cl	
Study or Subgroup 2.2.1 Active control Alanbay,2020	S <u>Mean</u> 110.6	SSNB SD 35.5	<u>Total</u> 15	C <u>Mean</u> 127.3	SD 35.1	15	12.7%	IV, Random, 95% CI -16.70 [-41.96, 8.56]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009	S <u>Mean</u> 110.6 140.4	SSNB SD 35.5 25.9	<u>Total</u> 15 5	C <u>Mean</u> 127.3 111	SD 35.1 16.6	15 5	12.7% 11.9%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020	Mean 110.6 140.4 62.5	35.5 25.9 15	<u>Total</u> 15 5 27	C <u>Mean</u> 127.3 111 77.4	SD 35.1 16.6 12.3	15 5 30	12.7% 11.9% 22.7%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014	<u>Mean</u> 110.6 140.4 62.5 171.3	35.5 25.9 15 13.6	Total 15 5 27 12	C <u>Mean</u> 127.3 111 77.4 159.6	SD 35.1 16.6 12.3 24.2	15 5 30 12	12.7% 11.9% 22.7% 18.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019	5 Mean 110.6 140.4 62.5 171.3 118.5	35.5 25.9 15 13.6 25.1	Total 15 5 27 12 20	C <u>Mean</u> 127.3 111 77.4 159.6 131	SD 35.1 16.6 12.3 24.2 28	15 5 30 12 10	12.7% 11.9% 22.7% 18.0% 15.2%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012	<u>Mean</u> 110.6 140.4 62.5 171.3	35.5 25.9 15 13.6 25.1	Total 15 5 27 12 20 18	C <u>Mean</u> 127.3 111 77.4 159.6	SD 35.1 16.6 12.3 24.2 28	15 5 30 12 10 18	12.7% 11.9% 22.7% 18.0% 15.2% 19.4%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019	5 Mean 110.6 140.4 62.5 171.3 118.5	35.5 25.9 15 13.6 25.1	Total 15 5 27 12 20	C <u>Mean</u> 127.3 111 77.4 159.6 131	SD 35.1 16.6 12.3 24.2 28	15 5 30 12 10 18	12.7% 11.9% 22.7% 18.0% 15.2% 19.4%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012	S Mean 110.6 140.4 62.5 171.3 118.5 128.9	35.5 25.9 15 13.6 25.1 22.9	Total 15 5 27 12 20 18 97	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 18	S Mean 110.6 140.4 62.5 171.3 118.5 128.9 1.25; Chi	35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20.	<u>Total</u> 15 5 27 12 20 18 97 15, df=	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44]	N, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI)	S Mean 110.6 140.4 62.5 171.3 118.5 128.9 1.25; Chi	35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20.	<u>Total</u> 15 5 27 12 20 18 97 15, df=	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 Test for overall effect: Z = 2.2.2 Placebo control	S Mean 110.6 140.4 62.5 171.3 118.5 128.9 1.25; Chi	35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20.	<u>Total</u> 15 5 27 12 20 18 97 15, df=	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 Test for overall effect: Z = 2.2.2 Placebo control Subtotal (95% Cl)	S Mean 110.6 140.4 62.5 171.3 118.5 128.9 11.25; Chi = 0.18 (P =	35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20.	Total 15 27 12 20 18 97 15, df =	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90 ; I <sup>2</sup> = 75	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44] -1.19 [-14.22, 11.84]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 Test for overall effect: Z = 2.2.2 Placebo control	5 <u>Mean</u> 110.6 140.4 62.5 171.3 118.5 128.9 11.25; Chi co.18 (P : cable	35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20. = 0.86)	Total 15 27 12 20 18 97 15, df =	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90 ; I <sup>2</sup> = 75	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44] -1.19 [-14.22, 11.84]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 Test for overall effect: Z = 2.2.2 Placebo control Subtotal (95% Cl) Heterogeneity: Not applin Test for overall effect: No	5 <u>Mean</u> 110.6 140.4 62.5 171.3 118.5 128.9 11.25; Chi co.18 (P : cable	35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20. = 0.86)	Total 15 5 27 12 20 18 97 15, df=	C <u>Mean</u> 127.3 111 77.4 159.6 131 125.8	SD 35.1 16.6 12.3 24.2 28 17.6	15 5 30 12 10 18 90 ; I <sup>2</sup> = 75	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% CI -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44] -1.19 [-14.22, 11.84] Not estimable	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 Test for overall effect: Z = 2.2.2 Placebo control Subtotal (95% Cl) Heterogeneity: Not applin Test for overall effect: Not Subtotal (95% Cl)	5 <u>Mean</u> 110.6 140.4 62.5 171.3 118.5 128.9 1.25; Chi 2.25; Chi 2.	SSNB SD 35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20. = 0.86)	Total 15 5 27 12 20 18 97 15, df= 0 97	C Mean 127.3 111 77.4 159.6 131 125.8 5 (P =	SD 35.1 16.6 12.3 24.2 28 17.6 0.001)	15 5 30 12 10 18 90 ; I <sup>2</sup> = 75 0	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% Cl -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44] -1.19 [-14.22, 11.84]	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 C2.2 Placebo control Subtotal (95% Cl) Heterogeneity: Not applin Test for overall effect: No Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18	5 <u>Mean</u> 110.6 140.4 62.5 171.3 118.5 128.9 11.25; Chi cable t applical	SSNB SD 35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20. ble i <sup>2</sup> = 20.	Total 15 5 27 12 20 18 97 15, df= 0 97 15, df=	C Mean 127.3 111 77.4 159.6 131 125.8 5 (P =	SD 35.1 16.6 12.3 24.2 28 17.6 0.001)	15 5 30 12 10 18 90 ; I <sup>2</sup> = 75 0	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% CI -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44] -1.19 [-14.22, 11.84] Not estimable	IV, Random, 95% Cl
Study or Subgroup 2.2.1 Active control Alanbay,2020 Boonsong,2009 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 18 Test for overall effect: Z = 2.2.2 Placebo control Subtotal (95% Cl) Heterogeneity: Not applin Test for overall effect: No	5 <u>Mean</u> 110.6 140.4 62.5 171.3 118.5 128.9 1.25; Chi cable tapplical 1.25; Chi cable tapplical	SSNB SD 35.5 25.9 15 13.6 25.1 22.9 i <sup>2</sup> = 20. = 0.86j	Total 15 27 12 20 97 15, df= 97 15, df=	C Mean 127.3 111 77.4 159.6 131 125.8 5 (P =	SD 35.1 16.6 12.3 24.2 28 17.6 0.001)	15 5 30 12 10 18 90 ; I <sup>2</sup> = 75 0	12.7% 11.9% 22.7% 18.0% 15.2% 19.4% 100.0%	V, Random, 95% CI -16.70 [-41.96, 8.56] 29.40 [2.44, 56.36] -14.90 [-22.07, -7.73] 11.70 [-4.01, 27.41] -12.50 [-33.05, 8.05] 3.10 [-10.24, 16.44] -1.19 [-14.22, 11.84] Not estimable	IV, Random, 95% Cl

controls and six active controls. The active control treatment included ultrasound treatment (16), intra-articular hyaluronic acid (HA) injection (15), intra-articular shoulder methyl prednisolone acetate injection (9), suprascapular nerve pulsed radiofrequency (11), botulinum toxin-A (BoNT-A) injection (10), and glenohumeral joint triamcinolone acetonide injection (13). The baseline details of the included studies are displayed in **Table 1**.

#### Primary Endpoint of Visual Analog Scale

VAS was an endpoint in all the eight included studies. For effects of SSNB on HSP within 4 wk, a total of 251 patients participated. For effects no less than 4 wk, 281 participated. As shown in **Figure 2**, there was no obvious difference between SSNB group and active control group regardless of the follow-up period (<4

or  $\geq$ 4 wk), which were -1.64 (-10.67, 7.39; *p* = 0.72) and 7.91 (-11.89, 27.70; *p* = 0.43), but when compared with placebo, the SSNB showed obvious benefits than control group despite the follow-up period (<4 or  $\geq$ 4 wk), and the corresponding mean differences (and 95% CI) were -19.41 (-30.38, -8.44; *p* = 0.0005) and -17.07 (-27.70, -6.44; *p* = 0.002) (**Figure 2**).

## **Secondary Endpoints**

The secondary endpoint we were interested in mainly included PROM of abduction, flexion, and external rotation. In addition, the indicator FMA reflecting the motor function was also a secondary outcome. For abduction, flexion, or external rotation ROM, similar with VAS, the difference between SSNB and active group was not statistically significant, which were 2.08 (-5.18, 9.33; p = 0.57), 5.42 (-4.51, 15.34; p = 0.28), and -3.24 (-8.41,

	S	SNB		C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	-		Total				Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
3.1.1 Active control									
Boonsong,2009	149.6	13.9	5	120.6	30.3	5	10.4%	29.00 [-0.22, 58.22]	
Kim,2014	165.8	10.8		156.7		12	26.4%	9.10 [-7.56, 25.76]	
Sencan,2019	147	21.6	20	145	30	10	18.5%	2.00 [-18.86, 22.86]	<b>_</b>
Tubay,2012	128.6	19.2	18	129.4	14.6	18	44.7%	-0.80 [-11.94, 10.34]	
Subtotal (95% CI)			55			45	100.0%	5.42 [-4.51, 15.34]	◆
Heterogeneity: Tau <sup>2</sup> =	24.98; 0	Chi² = :	3.92, df	= 3 (P =	= 0.27)	; 1= 23	3%		
Test for overall effect:	Z=1.07	(P = 0	.28)						
3.1.2 Placebo control	ı								
Subtotal (95% CI)	•		0			0		Not estimable	
Heterogeneity: Not ap	nlicable								
Test for overall effect:									
Total (95% CI)			55			45	100.0%	5.42 [-4.51, 15.34]	◆
Heterogeneity: Tau² =				'= 3 (P =	= 0.27)	$ ^{2} = 23$	3%		-100 -50 0 50 100
Test for overall effect:		•							Hazards [SSNB] Hazards [Control]
Test for subaroup diff	erences	: Not a	apilaa	ole					
Test for subaroup diff Flexion R	erences OM >	:Nota 4 V	bolicat Veel	ole ∢S					
Test for subaroup diff Flexion R	OM≥	:4 v isnb	veel	KS C	ontrol			Mean Difference	Mean Difference
Test for subaroup diff Flexion R <sup>4</sup> Study or Subgroup	OM≥	:4 v isnb	veel	KS C		Total	Weight	Mean Difference IV, Random, 95% Cl	
Flexion R	OM≥ s	:4 v isnb	veel	KS C		Total	Weight		Mean Difference
Flexion R <sup>4</sup> Study or Subgroup 3.2.1 Active control Alanbay,2020	OM ≥ s <u>Mean</u> 118.6	:4 т snb sd 30	Veeł <u>Total</u> 15	≦S Co <u>Mean</u> 134.6	SD 34.4	15	15.8%	IV, Random, 95% Cl	Mean Difference
Flexion R <sup>4</sup> Study or Subgroup 3.2.1 Active control Alanbay,2020 Boonsong,2009	OM ≥ s <u>Mean</u> 118.6 156.4	:4 V SNB SD 30 12.5	Vee <u>Total</u> 15 5	∑S <u>Co</u> <u>Mean</u> 134.6 128	SD 34.4 26.6	15 5	15.8% 13.8%	IV, Random, 95% CI -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16]	Mean Difference
Flexion R <sup>4</sup> Study or Subgroup 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014	OM > s <u>Mean</u> 118.6 156.4 178.3	30 3.9	Veel <u>Total</u> 15 5 12	∑S <u>Mean</u> 134.6 128 166.7	SD 34.4 26.6 23.1	15 5 12	15.8% 13.8% 25.8%	V, Random, 95% CI -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019	OM S <u>Mean</u> 118.6 156.4 178.3 137.5	30 30 12.5 3.9 22.3	Veel Total 15 5 12 20	∑S <u>Mean</u> 134.6 128 166.7 139	SD 34.4 26.6 23.1 31	15 5 12 10	15.8% 13.8% 25.8% 17.0%	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012	OM > s <u>Mean</u> 118.6 156.4 178.3	30 30 12.5 3.9 22.3	Veel <u>Total</u> 15 5 12 20 18	∑S <u>Mean</u> 134.6 128 166.7	SD 34.4 26.6 23.1 31	15 5 12 10 18	15.8% 13.8% 25.8% 17.0% 27.6%	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI)	OM S <u>Mean</u> 118.6 156.4 178.3 137.5 128.6	30 30 12.5 3.9 22.3 20.5	Vee <u>Total</u> 15 5 12 20 18 <b>70</b>	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b>	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> =	Mean 118.6 156.4 178.3 137.5 128.6 100.83;	4 V SNB SD 12.5 3.9 22.3 20.5 Chi <sup>2</sup> =	Vee <u>Total</u> 15 5 12 20 18 <b>70</b> \$9.15, 0	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b>	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69]	Mean Difference
Flexion R <sup>4</sup> Study or Subgroup 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014	Mean 118.6 156.4 178.3 137.5 128.6 100.83;	4 V SNB SD 12.5 3.9 22.3 20.5 Chi <sup>2</sup> =	Vee <u>Total</u> 15 5 12 20 18 <b>70</b> \$9.15, 0	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b>	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control	OM → s <u>Mean</u> 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53	4 V SNB SD 12.5 3.9 22.3 20.5 Chi <sup>2</sup> =	Vee <u>Total</u> 15 5 12 20 18 70 9.15, 0 .59)	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b> 6); I <sup>2</sup> = 9	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control Subtotal (95% CI)	()M → <u>Mean</u> 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53 I	:4 v ssns sp 12.5 3.9 22.3 20.5 Chi <sup>2</sup> = (P = 0	Vee <u>Total</u> 15 5 12 20 18 <b>70</b> \$9.15, 0	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b>	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control	()M → <u>Mean</u> 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53 I	:4 v ssns sp 12.5 3.9 22.3 20.5 Chi <sup>2</sup> = (P = 0	Vee <u>Total</u> 15 5 12 20 18 70 9.15, 0 .59)	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b> 6); I <sup>2</sup> = 9	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69] 3.28 [-8.77, 15.33]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control Subtotal (95% CI) Heterogeneity: Not ap	()M → S Mean 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53 I pplicable	4 V SNB 30 12.5 3.9 22.3 20.5 Chi <sup>2</sup> = (P = 0	Vee <u>Total</u> 15 5 12 20 18 70 9.15, 0 .59) 0	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 18 <b>60</b> 6); I <sup>2</sup> = 9	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69] 3.28 [-8.77, 15.33]	Mean Difference
Flexion R <sup>4</sup> Study or Subgroup 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect:	()M → S Mean 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53 I pplicable	4 V SNB 30 12.5 3.9 22.3 20.5 Chi <sup>2</sup> = (P = 0	Vee <u>Total</u> 15 5 12 20 18 70 9.15, 0 .59) 0	∑S <u>Mean</u> 134.6 128 166.7 139 131.7	34.4 26.6 23.1 31 15.2	15 5 12 10 8 <b>60</b> 6); I <sup>2</sup> = 9	15.8% 13.8% 25.8% 17.0% 27.6% <b>100.0</b> %	V, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69] 3.28 [-8.77, 15.33]	Mean Difference
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control Subtotal (95% CI) Heterogeneity: Not ap Test for overall effect: Total (95% CI)	()M → S Mean 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53 I pplicable Not app	$(4 ) = \frac{30}{50}$ $(7) = \frac{30}{12.5}$ (22.3) = 22.3 (22.3) = 22.3	Veel <u>Total</u> 15 5 12 20 18 70 9.15, 0 .59) 0 70	S Co Mean 134.6 128 166.7 139 131.7 df = 4 (P	SD 34.4 26.6 23.1 31 15.2 = 0.00	15 5 12 10 18 <b>60</b> 6); I <sup>2</sup> = 9 0	15.8% 13.8% 25.8% 17.0% 27.6% 100.0% 56%	IV, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69] 3.28 [-8.77, 15.33] Not estimable	Mean Difference IV, Random, 95% CI
Flexion R <sup>4</sup> <u>Study or Subgroup</u> 3.2.1 Active control Alanbay,2020 Boonsong,2009 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 3.2.2 Placebo control Subtotal (95% CI)	()M → S Mean 118.6 156.4 178.3 137.5 128.6 100.83; Z = 0.53 I pplicable Not app 100.83;	$(4 \ V)^{30}$ $(4 \ V)^{30}$ $(12.5 \ 3.9 \ 22.3 \ 20.5 \ (P = 0 \ 10)^{2}$ $(P = 0 \ (P = 0 \ 10)^{2}$	Veel <u>Total</u> 15 5 12 20 18 70 9.15, 0 0 70 9.15, 0 9.15, 0	S Co Mean 134.6 128 166.7 139 131.7 df = 4 (P	SD 34.4 26.6 23.1 31 15.2 = 0.00	15 5 12 10 18 <b>60</b> 6); I <sup>2</sup> = 9 0	15.8% 13.8% 25.8% 17.0% 27.6% 100.0% 56%	IV, Random, 95% Cl -16.00 [-39.10, 7.10] 28.40 [2.64, 54.16] 11.60 [-1.65, 24.85] -1.50 [-23.06, 20.06] -3.10 [-14.89, 8.69] 3.28 [-8.77, 15.33] Not estimable	Mean Difference

1.94; p = 0.22) in a follow-up less than 4 wk. When the follow-up period extended to over 4 wk, there were still no differences, and the mean differences (and 95% CI) were -1.19 (-14.22, 11.84; p = 0.86), -1.19 (-14.22, 11.84; p = 0.59), and -4.45 (-15.89, 6.99; p = 0.45) separately. For motor function of FMA, only two studies reported the outcome, and the FMA scores in SSNB group was -2.59 (-4.52, -0.66) less than those in active group (**Figures 3–6**).

#### **Publication Bias and Quality Assessment**

A funnel plot was employed to test the publication bias, as shown in **Supplementary Material**. No obvious publication bias was observed. For quality assessment, we noticed that all the published articles had a high performance bias (**Supplementary Material**).

#### **Sensitivity Analysis**

We performed sensitivity analysis for the primary endpoint VAS and found that our results were robust (**Supplementary Material**).

## DISCUSSION

At present, SSNB is widely used in patients with chronic shoulder pain or frozen shoulder and gains excellent clinical effects (17, 18), but the application of SSNB in HSP patients is relatively rare. To the best of our knowledge, the present meta-analysis is the first one to investigate the effectiveness of SSNB vs. other treatments for HSP. In the analysis, we found that SSNB is an effective way to alleviate HSP at a longest follow-up period of 12 wk.

Suprascapular nerve is a mixed nerve fiber containing afferent and efferent content, and it originates from the upper trunk of

Study or Subgroup         Mean         SD         Total         Mean         SD         Total         Weight         N. Random, 95% CI         N. Random, 95% CI           Kasapoglu-Aksoy,2020         40.7         16.3         27         46.2         9.8         30         53.5%         -5.50 [+12.58, 1.58]           Kim,2014         7.38         22         12         88.8         18.7         12         10.0%         5.00 [+17.99, 7.99]           Subtoral (95% CI)         77         70         100.0%         -3.24 [-8.41, 1.94]		S	SNB		С	ontrol			Mean Difference	Mean Difference
$\begin{aligned} \text{Kasapoglu-Aksoy,2020} & 40.7 & 16.3 & 27 & 46.2 & 9.8 & 30 & 53.5\% & -5.50 [+2.58, 1.58] \\ \text{Kim,2014} & 73.8 & 22 & 12 & 68.8 & 18.7 & 12 & 10.0\% & 5.00 [+7.13, 21.34] \\ \text{Sencan,2019} & 64 & 15.2 & 20 & 69 & 18 & 05.4 & 16.3 & 18 & 20.5\% & 0.00 [+11.43, 11.43] \\ \text{Tubay,2012} & 59.4 & 18.6 & 18 & 59.4 & 16.3 & 18 & 20.5\% & 0.00 [+11.43, 11.43] \\ \text{Heterogeneily, Tau" = 0.00; Chi" = 1.75, dif = 3 (P = 0.63); P = 0\% \\ \text{Test for overall effect } Z = 1.22 (P = 0.22) \\ \text{4.1.2 Placebo control} \\ \text{Subtotal (95\% CI)} & 0 & 0 \\ \text{Heterogeneily, Tau" = 0.00; Chi" = 1.75, dif = 3 (P = 0.63); P = 0\% \\ \text{Test for overall effect } Z = 1.22 (P = 0.22) \\ \text{Total (95\% CI)} & 0 & 0 \\ \text{Kim, 2014} & \text{Not applicable} \\ \text{Total (95\% CI)} & 0 & 0 \\ \text{Kudy or Subgroup} & Mean & SD & Total & Mean & SD & Total & Weight \\ \text{Kasapoglu-Aksoy,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Aanabay,2020} & 59 & 17 & 15 & 69 & 22.5 & 15 & 17.9\% & -10.00 [-24.27, 4.27] \\ \text{Heterogeneily, Tau" = 137.13; Chi" = 22.76, dif = 4 (P = 0.0001); P = 82\% \\ \text{Total (95\% CI)} & 92 & 85 & 100.0\% & -4.45 [-15.89, 6.99] \\ \text{Heterogeneily, Tau" = 137.13; Chi" = 22.76, dif = 4 (P = 0.0001); P = 82\% \\ \text{Test for overall effect X applicable} \\ \text{Total (95\% CI)} & 92 & 85 & 100.0\% & -4.45 [-15.89, 6.99] \\ \text{Heterogeneily, Tau" = 137.13; Chi" = 22.76, dif = 4 (P = 0.0001); P = 82\% \\ \text{Test for overall effect X applicable} \\ \text{Total (95\% CI)} & 92 & 85 & 100.0\% &$	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	4.1.1 Active control									
Sencan, 2019 64 15.2 20 69 18 10 15.9% - 5.00 [-17.99, 799] Tubay, 2012 59.4 18.6 18 59.4 16.3 18 20.5% 0.00 [-11.43, 11.43] Tubay, 2012 59.4 18.6 18 59.4 16.3 18 20.5% 0.00 [-11.43, 11.43] Total (95% CI) 77 70 100.0% .3.24 [-8.41, 1.94] Heterogeneity, Tau" = 0.00; Chi" = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect Z = 1.22 (P = 0.22) 4.1.2 Placebo control Subtotal (95% CI) 0 0 0 Not estimable Heterogeneity, Tau" = 0.00; Chi" = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for subgroup differences: Not applicable SNRE Control Mean Difference SNRE Control Alanbay,2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kim,2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [2.94, 22.86] Sencan,2019 59 16.2 20 67 19 10 18.3% -8.00 [-21.75, 5.75] Tubay,2012 61.1 17.1 18 62.2 16.3 18 20.3% -11.01 [-2.01, 9.81] Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau" = 137.13; Chi" = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau" = 137.13; Chi" = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect X tot applicable Test for overall effect	Kasapoglu-Aksoy,2020	40.7	16.3	27	46.2	9.8	30	53.5%	-5.50 [-12.58, 1.58]	
Tubay, 2012 59.4 18.6 18 59.4 16.3 18 20.5% 0.00 $(\frac{1}{1}, 43, \frac{1}{1}, 43, \frac{1}{$	Kim,2014	73.8	22	12	68.8	18.7	12	10.0%	5.00 [-11.34, 21.34]	
Subtotal (95% CI) 77 70 100.0% -3.24 [-8.41, 1.94] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect Z = 1.22 (P = 0.22) 4.12 Placebo control Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Test for overall effect Z = 1.22 (P = 0.22) Total (95% CI) 77 70 100.0% -3.24 [-8.41, 1.94] Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for subaroug differences: Not applicable Ext Cernal rotation $\neq$ Weeks SSNB Control Mean Difference SSNB Control Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight V, Random, 95% Cl 4.2.1 Active control Anahazy.2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kasapoglu-Aksoy.2020 35 15 27 51.2 12.3 30 22.6% -16.20 [-23.37, -9.03] Kim,2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [2.94, 22.86] Sencen,2019 59 16.2 20 67 19 10 16.3% -8.00 [-21.75, 5.75] Tubay.2012 61.1 17.1 18 62.2 16.3 18 20.3% -1.10 [-12.01, 9.81] Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect Z = 1.76, 6(P = 0.45) 4.2.2 Placebo control Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect Z = 0.76, 6(P = 0.45) 4.2.2 Placebo control Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect Z = 0.76, 6(P = 0.45) 4.2.2 Placebo control Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect Z = 0.76, 0 = 0.45) Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect Z = 0.76, 0 = 0.000 Heterogeneity: T	Sencan,2019	64	15.2	20	69	18	10	15.9%	-5.00 [-17.99, 7.99]	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect Z = 1.22 (P = 0.22) 4.12 Placebo control Subtotal (95% Cl) 0 0 0 Not estimable Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for overall effect Z = 1.22 (P = 0.22) Test for subaroup differences: Not applicable EX LOTIAL I OTIAL I OTIAL Week S SNB Control Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight N. Random, 95% Cl 4.2.1 Active control Anabay.2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kim.2014 87.5 4.6 12 74.6 17 12 20.9% 12.00 [-24.27, 4.27] Kim.2014 87.5 4.6 12 74.6 17 12 0.09% 12.00 [-24.27, 4.27] Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect X = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 92 85 100.0% -4.45 [-15.89, 6.99] Heteropaneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup>	Tubay,2012	59.4	18.6		59.4	16.3	18	20.5%		
Test for overall effect: $Z = 1.22$ (P = 0.22) 4.1.2 Placebo control Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Total (95% CI) 77 70 100.0% -3.24 [-8.41, 1.94] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0.% Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Tubay.2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kasapoglu-Aksoy.2020 35 15 27 51.2 12.3 30 22.6% -16.20 [-23.77, -0.03] Kim,2014 87.5 4.6 12 74.6 17 112 20.9% 12.02 (9.4, 22.86] Sencan,2019 59 16.2 20 67 19 10 18.3% -8.00 [-21.75, 5.75] Tubay.2012 61.1 17.1 18 62.2 16.3 18 20.3% -1.10 [-12.01, 9.81] Subtotal (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect: Not applicable Test for overall effect. Not applicable T	Subtotal (95% CI)			77			70	100.0%	-3.24 [-8.41, 1.94]	•
Subtotal (95% CI)       0       0       Not estimable         Heterogeneity: Not applicable       Total (95% CI)       77       70       100.0%       -3.24 [-8.41, 1.94]         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0%       -3.24 [-8.41, 1.94]       -100       -50       50       100         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0%       Total (95% CI)       -0       -50       50       100         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0%       Total (95% CI)       Mean Differences: Not applicable       Mean Difference       Mean Difference         Ext termal       rotat 100       4       Weeks       Weeks       Mean Difference       Me		•			P = 0.63	3); l² =	0%			
Heterogeneity: Not applicable Test for overall effect: Not applicable Total (95% CI) 77 70 100.0% -3.24 [-8.41, 1.94] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.75, df = 3 (P = 0.63); P = 0% Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for overall effect: Z = 1.22 (P = 0.22) Test for subtoral (100 $\rightarrow$ 4 Weeks SSNB Control Mean SD Total Weight V. Random, 95% CI V. Random, 95% CI V. Random, 95% CI 4.2.1 Active control Alanbay.2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kasapoglu-Aksoy.2020 35 15 27 51.2 12.3 30 22.6% -16.20 [-23.37, -9.03] Kim.2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [-24.27, 8.26] Subtoral (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Ch <sup>2</sup> = 22.76, df = 4 (P = 0.0001); P = 82% Test for overall effect: Not applicable Test for over				0			0		Not estimable	
Total (95% CI)       77       70       100.0%       -3.24 [-8.41, 1.94]         Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); I <sup>2</sup> = 0%         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 1.22 (P = 0.22)         Test for overall effect: Z = 0.76 (P = 0.45)         Mean SD Total Mean SD Total Mean SD Total Mean Mean SD Total Mean Mean Difference         Mean Difference         SSNB       Control       Mean Difference         Kasapoglu-Aksoy.2020       59       17       15       69       12.90 (2.24, 2.7, 4.27]         Kim/201       8       10.00 [24.27, 4.27]       Kim/201 (2.29	Heterogeneity: Not applic		hlo	Ŭ			0		notestimable	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.75, df = 3 (P = 0.63); l <sup>2</sup> = 0% Test for overall effect Z = 1.22 (P = 0.22) Test for suboroup differences: Not applicable EX ternal rotation $\stackrel{>}{\rightarrow}$ Weeks SSNB Control Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean SD Total Weight V, Random, 95% Cl 4.2.1 Active control Alanbay, 2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kasapoglu-Aksoy, 2020 35 15 27 51.2 12.3 30 22.6% -16.20 [-23.37, -9.03] Kim, 2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [2.94, 22.86] Sencan, 2019 59 16.2 20 67 19 10 18.3% -8.00 [-21.75, 5.75] Tubay, 2012 61.1 17.1 18 62.2 16.3 18 20.3% -11.0 [-12.01, 9.81] Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Test for overall effect: Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Test for overall effect: Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% Cl) 92 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82%		applica	Jie	77			70	100.0%	-3.24 [-8.41, 1.94]	•
Test for overall effect: $Z = 1.22$ (P = 0.22) Test for subgroup differences: Not applicable EXternal rotation $\stackrel{>}{>}4$ Weeks SSNB Control Mean <u>SD Total Mean SD Total Weight</u> <u>N. Random, 95% Cl</u> 4.2.1 Active control Alanbay, 2020 59 17 15 69 22.5 15 17.9% -10.00 [-24.27, 4.27] Kasapoglu-Aksoy, 2020 35 15 27 51.2 12.3 30 22.6% -16.20 [-23.37, -9.03] Kim, 2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [2.94, 22.86] Sencan, 2019 59 16.2 20 67 19 10 18.3% -8.00 [-21.75, 5.75] Tubay, 2012 61.1 17.1 18 62.2 16.3 18 20.3% -1.10 [-12.01, 9.81] Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Not applicable Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 0 50 100	•	0: Chi <sup>2</sup> =	1.75		P = 0.6	3); l² =				
Test for subgroup differences: Not applicable         Hazards (control         Mean SD Total Mean SD Total Weight       Mean Difference       Mean Difference         SSNB       Control       Mean Difference       Mean Difference         Study or Subgroup       Mean SD Total Weight       Ny, Random, 95% CI       Ny, Random, 95% CI         Alanbay, 2020       59 17       15       69 22.5       15       17.13       69 22.5       15       17.13       69 22.5       15       17.13       69 22.5       15       17.13       69 22.5       15       17.12       2.0.9%       1.0.00 [-24.27, 4.27]         Kim, 2014       87.5       N       1.0.00 [-24.27, 4.27]         Kim, 2014       87.5       1.0.1       N, Random, 95% CI       N, Random, 95% CI         Tubay, 2012       61.1       17.1       18       2.2.76, df = 4 (P = 0.0001); IP = 82%         Total (95% C					0.01	-// -	• •			
External rotation $\ge 4$ weeks         SSNB       Control       Mean Difference         Study or Subgroup       Mean SD Total Mean       SD Total Weight       Mean Difference         ALActive control         Alanbay,2020       59       17       15       69       22.5       15       17.9%       -10.00 [-24.27, 4.27]         Kasapoglu-Aksoy,2020       35       15       27       51.2       12.3       30       22.6%       -16.20 [-23.37, -9.03]         Kim,2014       87.5       4.6       12       74.6       17       12       20.9%       12.90 [2.94, 22.86]         Sencan,2019       59       16.2       20       67       19       10       18.3%       -8.00 [-21.75, 5.75]         Tubay,2012       61.1       17.1       18       62.2       16.3       18       20.3%       -1.10 [-12.01, 9.81]         Subtotal (95% Cl)       92       85       100.0%       -4.45 [-15.89, 6.99]       -         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%       -       -       4.45 [-15.89, 6.99]       -         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%       -										Hazarde (SSNR) Hazarde (Control)
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Test for subaroup differen	nces: No	t appli	cable						Hazards (SSND) Hazards (Control)
Study or Subgroup         Mean         SD         Total         Mean         SD         Total         Weight         IV, Random, 95% CI         IV, Random, 95% CI           4.2.1 Active control         Alanbay, 2020         59         17         15         69         22.5         15         17.9% $-10.00$ [-24.27, 4.27]         Kasapoglu-Aksoy, 2020         35         15         27         51.2         12.3         30         22.6% $-16.20$ [-23.37, -9.03]         Image: constant of the start of the s					wee	eks				
4.2.1 Active control         Alanbay,2020       59       17       15       69       22.5       15       17.9% $-10.00$ [-24.27, 4.27]         Kasapoglu-Aksoy,2020       35       15       27       51.2       12.3       30       22.6% $-16.20$ [-23.37, $-9.03$ ]         Kim,2014       87.5       4.6       12       74.6       17       12       20.9%       12.90 [2.94, 22.86]         Sencan,2019       59       16.2       20       67       19       10       18.3% $-8.00$ [-21.75, 5.75]         Tubay,2012       61.1       17.1       18       62.2       16.3       18       20.3% $-1.10$ [-12.01, 9.81]         Subtotal (95% CI)       92       85       100.0% $-4.45$ [-15.89, 6.99]       -         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%       Test for overall effect: Not applicable       -         Test for overall effect: Not applicable       92       85       100.0% $-4.45$ [-15.89, 6.99]       -         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%       -       -       -       -         Total (95% CI)       92       85       100.0%       -4.45 [-15.89, 6.99]       -       - <td></td> <td>tati</td> <td>ion</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Mean Difference</td> <td></td>		tati	ion						Mean Difference	
Alanbay,2020 59 17 15 69 22.5 15 17.9% $-10.00$ [-24.27, 4.27] Kasapoglu-Aksoy,2020 35 15 27 51.2 12.3 30 22.6% $-16.20$ [-23.37, -9.03] Kim,2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [2.94, 22.86] Sencan,2019 59 16.2 20 67 19 10 18.3% $-8.00$ [-21.75, 5.75] Tubay,2012 61.1 17.1 18 62.2 16.3 18 20.3% $-1.10$ [-12.01, 9.81] Subtotal (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect: Not applicable Test for overall effect: Not applicable Total (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%	External ro	tati s	ion SNB	≥4	C	ontrol	Total	Weight		Mean Difference
Kasapoglu-Aksoy,2020 35 15 27 51.2 12.3 30 22.6% $-16.20$ [-23.37, -9.03] Kim,2014 87.5 4.6 12 74.6 17 12 20.9% 12.90 [2.94, 22.86] Sencan,2019 59 16.2 20 67 19 10 18.3% $-8.00$ [-21.75, 5.75] Tubay,2012 61.1 17.1 18 62.2 16.3 18 20.3% $-1.10$ [-12.01, 9.81] Subtotal (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect: Not applicable Test for overall effect: Not applicable Total (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% CI) 92 85 100.0% $-4.45$ [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%	External ro Study or Subgroup	tati s	ion SNB	≥4	C	ontrol	Total	Weight		Mean Difference
Kim,2014 $87.5$ $4.6$ $12$ $74.6$ $17$ $12$ $20.9\%$ $12.90$ $22.86$ Sencan,2019 $59$ $16.2$ $20$ $67$ $19$ $10$ $18.3\%$ $-8.00$ $[-21.75, 5.75]$ Tubay,2012 $61.1$ $17.1$ $18$ $62.2$ $16.3$ $18$ $20.3\%$ $-1.10$ $[-12.01, 9.81]$ Subtotal (95% CI)       92 $85$ $100.0\%$ $-4.45$ $[-15.89, 6.99]$ Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%       Test for overall effect: Not applicable         Total (95% CI)       0       0       Not estimable         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% $-4.45$ $-15.89, 6.99$ Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% $-4.45$ $-15.89, 6.99$	External ro <u>Study or Subgroup</u> 4.2.1 Active control	tati s Mean	LON SNB SD	≥4 Total	Co Mean	ontrol SD			IV, Random, 95% Cl	Mean Difference
Sencan, 2019 59 16.2 20 67 19 10 18.3% -8.00 [-21.75, 5.75] Tubay, 2012 61.1 17.1 18 62.2 16.3 18 20.3% -1.10 [-12.01, 9.81] Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect: Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99]	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020	tati s <u>Mean</u> 59	LON SNB SD 17	≥4 <u>Total</u> 15	Co Mean 69	ontrol SD 22.5	15	17.9%	IV, Random, 95% CI -10.00 [-24.27, 4.27]	Mean Difference
Tubay,2012 $61.1$ $17.1$ $18$ $62.2$ $16.3$ $18$ $20.3\%$ $-1.10[-12.01], 9.81]$ Subtotal (95% CI)       92 $85$ $100.0\%$ $-4.45$ $[-15.89, 6.99]$ Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82%       Test for overall effect: $Z = 0.76$ (P = 0.45)         4.2.2 Placebo control       0       0       Not estimable         Heterogeneity: Not applicable       0       0       Not estimable         Total (95% CI)       92       85 $100.0\%$ $-4.45$ $[-15.89, 6.99]$ Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% $-4.45$ $[-15.89, 6.99]$ Total (95% CI)       92       85 $100.0\%$ $-4.45$ $[-15.89, 6.99]$ Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% $-100$ $-50$ $0$ $50$ $100$	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020	otati s <u>Mean</u> 59 35	LON SNB SD 17 15	≥4 <u>Total</u> 15 27	Co <u>Mean</u> 69 51.2	22.5 12.3	15 30	17.9% 22.6%	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03]	Mean Difference
Subtotal (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Test for overall effect: Z = 0.76 (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82%	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014	0tati s <u>Mean</u> 59 35 87.5	LON SNB SD 17 15 4.6	≥4 <u>Total</u> 15 27 12	69 51.2 74.6	22.5 12.3 17	15 30 12	17.9% 22.6% 20.9%	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86]	Mean Difference
Test for overall effect: $Z = 0.76$ (P = 0.45)         4.2.2 Placebo control         Subtotal (95% Cl)       0         Heterogeneity: Not applicable         Total (95% Cl)       92         85       100.0%         -4.45 [-15.89, 6.99]         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82%         Total (95% Cl)       92         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82%	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019	0tati s <u>Mean</u> 59 35 87.5 59	LON SSNB SD 17 15 4.6 16.2	≥4 <u>Total</u> 15 27 12 20	69 51.2 74.6 67	22.5 12.3 17 19	15 30 12 10	17.9% 22.6% 20.9% 18.3%	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75]	Mean Difference
Test for overall effect: $Z = 0.76$ (P = 0.45) 4.2.2 Placebo control Subtotal (95% Cl) 0 0 Not estimable Heterogeneity: Not applicable Total (95% Cl) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% Cl) 92 0 50 100	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012	0tati s <u>Mean</u> 59 35 87.5 59	LON SSNB SD 17 15 4.6 16.2	≥4 <u>Total</u> 15 27 12 20 18	69 51.2 74.6 67	22.5 12.3 17 19	15 30 12 10 18	17.9% 22.6% 20.9% 18.3% 20.3%	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81]	Mean Difference
Subtotal (95% CI) 0 0 Not estimable Heterogeneity: Not applicable Total (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Total (95% CI) 92 0 50 100	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI)	0tati <u>S</u> 59 35 87.5 59 61.1	LON SNB SD 17 15 4.6 16.2 17.1		69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 <b>85</b>	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81]	Mean Difference
Heterogeneity: Not applicable Test for overall effect: Not applicable Total (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82% Test for overall effect: 7 = 0.76 (P = 0.45) -100 -50 0 50 100	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 137	)tati s <u>Mean</u> 59 35 87.5 59 61.1 7.13; Chi	ION SNB SD 17 15 4.6 16.2 17.1 <sup>2</sup> = 22.		69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 <b>85</b>	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81]	Mean Difference
Test for overall effect: Not applicable Total (95% CI) 92 85 100.0% -4.45 [-15.89, 6.99] Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% -100 -50 0 50 100	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 137 Test for overall effect: Z =	)tati s <u>Mean</u> 59 35 87.5 59 61.1 7.13; Chi	ION SNB SD 17 15 4.6 16.2 17.1 <sup>2</sup> = 22.		69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 <b>85</b>	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81]	Mean Difference
Test for overall effect: Not applicable         Total (95% CI)       92       85       100.0%       -4.45 [-15.89, 6.99]         Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); I <sup>2</sup> = 82%       -100       -50       0       50       100	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 133 Test for overall effect: Z = 4.2.2 Placebo control	)tati s <u>Mean</u> 59 35 87.5 59 61.1 7.13; Chi	ION SNB SD 17 15 4.6 16.2 17.1 <sup>2</sup> = 22.	A     A     Total     15     27     12     20     18     92     76, df =	69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 <b>85</b> ); I <sup>2</sup> = 8	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% CI -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81] -4.45 [-15.89, 6.99]	Mean Difference
Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Test for overall effect 7 = 0.76 (P = 0.45)	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 137 Test for overall effect: Z = 4.2.2 Placebo control Subtotal (95% CI)	) tatj s <u>Mean</u> 59 35 87.5 59 61.1 7.13; Chi 0.76 (P=	ION SNB SD 17 15 4.6 16.2 17.1 <sup>2</sup> = 22.	A     A     Total     15     27     12     20     18     92     76, df =	69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 <b>85</b> ); I <sup>2</sup> = 8	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% CI -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81] -4.45 [-15.89, 6.99]	Mean Difference
Heterogeneity: Tau <sup>2</sup> = 137.13; Chi <sup>2</sup> = 22.76, df = 4 (P = 0.0001); l <sup>2</sup> = 82% Test for overall effect: 7 = 0.76 (P = 0.45)	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 137 Test for overall effect: Z = 4.2.2 Placebo control Subtotal (95% CI) Heterogeneity: Not applic	) tatj s <u>Mean</u> 59 35 87.5 59 61.1 7.13; Chi 0.76 (P = able	LON SNB SD 17 15 4.6 16.2 17.1 <sup>2</sup> = 22. = 0.45)	A     A     Total     15     27     12     20     18     92     76, df =	69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 <b>85</b> ); I <sup>2</sup> = 8	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% CI -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81] -4.45 [-15.89, 6.99]	Mean Difference
Test for overall effect: 7 = 0.76 (P = 0.45) -100 -50 0 50 100	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 137 Test for overall effect: Z = 4.2.2 Placebo control Subtotal (95% Cl) Heterogeneity: Not applic Test for overall effect: Not	) tatj s <u>Mean</u> 59 35 87.5 59 61.1 7.13; Chi 0.76 (P = able	LON SNB SD 17 15 4.6 16.2 17.1 <sup>2</sup> = 22. = 0.45)		69 51.2 74.6 67 62.2	22.5 12.3 17 19 16.3	15 30 12 10 18 85 );   <sup>2</sup> = 8 0	17.9% 22.6% 20.9% 18.3% 20.3% <b>100.0</b> %	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81] -4.45 [-15.89, 6.99] Not estimable	Mean Difference
Hazards [SSNB] Hazards [Control]	External ro <u>Study or Subgroup</u> 4.2.1 Active control Alanbay,2020 Kasapoglu-Aksoy,2020 Kim,2014 Sencan,2019 Tubay,2012 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 137 Test for overall effect: Z = 4.2.2 Placebo control Subtotal (95% CI) Heterogeneity: Not applic Test for overall effect: Not Total (95% CI)	) tatj s Mean 59 35 87.5 59 61.1 7.13; Chi 0.76 (P = able : applicat	In the second se		69 51.2 74.6 67 62.2 : 4 (P =	ontrol SD 22.5 12.3 17 19 16.3 0.0001	15 30 12 10 18 <b>85</b> ); I <sup>2</sup> = 8 0 85	17.9% 22.6% 20.9% 18.3% 20.3% 100.0%	V, Random, 95% Cl -10.00 [-24.27, 4.27] -16.20 [-23.37, -9.03] 12.90 [2.94, 22.86] -8.00 [-21.75, 5.75] -1.10 [-12.01, 9.81] -4.45 [-15.89, 6.99] Not estimable	Mean Difference IV, Random, 95% Cl

FIGURE 5 | Forest plot of external rotation ROM between SSNB and other treatment.

	S	SNB		Co	ontro	l		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Kasapoglu-Aksoy,2020	10	4	27	12.6	3.4	30	98.9%	-2.60 [-4.54, -0.66]	
Kim,2014	22.8	23	12	24.6	24	12	1.1%	-1.80 [-20.61, 17.01]	
Total (95% CI)			39			42	100.0%	-2.59 [-4.52, -0.66]	•
Heterogeneity: Tau <sup>2</sup> = 0.0	0; Chi² =	0.01	, df = 1	(P = 0.9)	33); l <sup>a</sup>	°= 0%			-100 -50 0 50 100
Test for overall effect: Z =	2.63 (P =	= 0.0	08)						Hazards [SSNB] Hazards [Control]
URE 6   Forest plot of FMA	hotwoor	001	IP and	othor tro	otmo	ot			

the brachial plexus (C5, C6). The motor of supraspinatus and infraspinatus muscles is innervated by the suprascapular nerve, which is the basic of SSNB for the treatment of HSP (9, 19, 20). Given the different mechanisms of SSNB vs. other treatments, the treatment effects may differ. SSNB just temporarily blocked

the suprascapular nerve; this may explain why the VAS failed to continue to decrease in the follow-up period more than 1 wk in the study by Adey-Wakeling et al. (8), but the VAS at weeks 1, 4, and 12 is much lower than baseline (about 30 vs. 69). In the study by Sencan et al. (9), the lowest VAS occurred in the second

week after SSNB procedure, and the VAS at week 8 is similar to that at week 2. In our study, we synthesized data from eight studies involving 281 patients followed up for at least 4 wk and demonstrated that the VAS in SSNB is not higher than that in the other treatments. The reason why the pain relief still works after 4 wk may be that the patients move more after the SSNB, and this helps to relieve HSP; even though the pain relief from SSNB disappeared after 4 wk, the pain relief from increased movement is still sustained (21).

Compared with intra-articular shoulder injection (IAI), SSNB may be much safer; SSNB does not have side effects caused by steroids used in the IAI (9, 22). Some complications like intraarticular infection, which is common in the other treatments, we found no such complications reported in articles about SSNB. Besides effects in HSP relief, SSNB also has the advantage of costeffectiveness; the current price of SSNB is much lower than that of other treatments like nerve pulsed radiofrequency treatment. It is also easy for the physical therapist to conduct the procedure.

In our analysis, we noticed that a combination of SSNB and other therapies may cause a better outcome. Sencan et al. (9) found that compared with SSNB or intra-articular shoulder injection (IAI), a combination of SSNB and IAI can reduce the VAS of HSP patients, although not different statistically, but the function of the shoulder improves significantly. Parashar et al. (23) divided 60 patients into three groups and found that SSNB in combination with non-invasive rehabilitation (NIR) is much more effective than either SSNB or NIR. One of the earliest studies about frozen shoulder also found that treatment with SSNB plus electroacupuncture is superior than any single one (24). Although the latter two studies focused on patients with chronic shoulder pain and frozen shoulder, it indicates that a combination of SSNB and other therapies may gain a better outcome.

The clinical benefits of injection guided by ultrasound or other equipment are still unknown. Compared with fluoroscopyguided injection, the ultrasound-guided injection causes less harm to the therapist (9). In our clinical practice, the use of ultrasound can help us with a clear view of the tissues and may be much safer. In a cross-sectional study, the researchers found that compared with conservative treatment, the ultrasound-guided SSNB can obviously improve the pain relief, but it does not prove the role of ultrasound in the SSNB, as the control group received conservative treatment (25). Kang et al. (18) found that SSNB by fluoroscopy-guided anterior approach can reduce the dose of local anesthetics and avoid pneumothorax, indicating that ultrasound-guided injection may be a better method. However, a study published in 2020 found that ultrasound-guided SSNB did not improve the VAS or the shoulder function compared

#### REFERENCES

 Wang L, Tao Y, Chen Y, Wang H, Zhou H, Fu X. Association of post stroke depression with social factors, insomnia, and neurological status in Chinese elderly population. *Neurol Sci.* (2016) 37:1305–10. doi: 10.1007/s10072-016-2590-1 with landmark-guided SSNB in chronic shoulder pain patients (26). More RCTs are needed to verify the validity of ultrasound-guided SSNB.

#### LIMITATIONS

The present meta-analysis has several limitations besides those inherent in the original studies. Firstly, some data in our study are transformed from the published articles, and this may cause the data to be not so accurate. Secondly, the control group patients received several kinds of treatment; this may introduce bias. Thirdly, our included studies reported no adverse events; it is impossible for us to investigate the safety of SSNB. Fourthly, the maximum follow-up period in our study is 12 wk; the efficacy of SSNB more than 3 months is unknown. Finally, the sample size in every study is small; this may introduce bias.

#### CONCLUSION

SSNB is an effective way for HSP patients.

#### DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

#### **AUTHOR CONTRIBUTIONS**

This study was designed by TZ. YH performed the study and wrote the manuscript. YW, XS, YL, and YY all participated in the study. All authors contributed to the article and approved the submitted version.

#### FUNDING

This study was supported by the 2021 Outstanding Talents Project of Xicheng District, Beijing (Fund No. 202131).

#### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur. 2021.723664/full#supplementary-material

- Viana R, Pereira S, Mehta S, Miller T, Teasell R. Evidence for therapeutic interventions for hemiplegic shoulder pain during the chronic stage of stroke: a review. *Top Stroke Rehabil.* (2012) 19:514–22. doi: 10.1310/tsr1906-514
- Snels IA, Beckerman H, Lankhorst GJ, Bouter LM. Treatment of hemiplegic shoulder pain in the Netherlands: results of a national survey. *Clin Rehabil.* (2000) 14:20–7. doi: 10.1191/026921500668239146

- Kalichman L, Ratmansky M. Underlying pathology and associated factors of hemiplegic shoulder pain. Am J Phys Med Rehab. (2011) 90:768–80. doi: 10.1097/PHM.0b013e31821 4e976
- Wilson RD, Chae J. Hemiplegic shoulder pain. Phys Med Rehabil Clin N Am. (2015) 26:641–55. doi: 10.1016/j.pmr.2015.06.007
- Coskun Benlidayi I, Basaran S. Hemiplegic shoulder pain: a common clinical consequence of stroke. *Pract Neurol.* (2014) 14:88–91. doi: 10.1136/practneurol-2013-000606
- Brown, D. E, James, D. C, Roy, S. Pain relief by suprascapular nerve block in gleno-humeral arthritis. *Scand J Rheumatol.* (1988) 17:411– 5. doi: 10.3109/03009748809105280
- Adey-Wakeling Z, Crotty M, Shanahan EM. Suprascapular nerve block for shoulder pain in the first year after stroke: a randomized controlled trial. *Stroke.* (2013) 44:3136–41. doi: 10.1161/STROKEAHA.113. 002471
- Sencan S, Celenlioglu AE, Karadag-Saygi E, Midi I, Gunduz OH. Effects of fluoroscopy-guided intraarticular injection, suprascapular nerve block, and combination therapy in hemiplegic shoulder pain: a prospective double-blind, randomized clinical study. *Neurol Sci.* (2019) 40:939– 46. doi: 10.1007/s10072-019-03733-6
- Kasapoglu-Aksoy M, Aykurt-Karlibel I, Altan L. Comparison of the efficacy of intramuscular botulinum toxin type-A injection into the pectoralis major and the teres major muscles and suprascapular nerve block for hemiplegic shoulder pain: a prospective, double-blind, randomized, controlled trial. *Neurol Sci.* (2020) 41:2225–30. doi: 10.1007/s10072-020-04334-4
- Alanbay, E, Aras, B, Kesikburun, S, Kizilirmak, S, Yasar, E, Tan, A. K. Effectiveness of Suprascapular Nerve Pulsed Radiofrequency Treatment for Hemiplegic Shoulder Pain: A Randomized-Controlled Trial. Pain physician (2020) 23 (3):245-252. doi: 10.36076/ppj.2020/23/245
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71
- Tubay A, Bal S, Bayram KB, Koçyigit H, Gürgan A. Suprascapular nerve block and glenohumeral injection in hemiplegic shoulder pain: To compare the effectiveness on pain and disability. *Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi.* (2012) 58:299–306. doi: 10.4274/tftr.54771
- Terlemez R, Çiftçi S, Topaloglu M, Dogu B, Yilmaz F, Kuran B. Suprascapular nerve block in hemiplegic shoulder pain: comparison of the effectiveness of placebo, local anesthetic, and corticosteroid injections—a randomized controlled study. *Neurol Sci.* (2020) 41:3243–7. doi: 10.1007/s10072-020-04362-0
- Kim SH, Kim DS. Suprascapular nerve block versus intra-articular hyaluronic acid injection in hemiplegic shoulder pain. *Brain Neurorehabil.* (2014) 7:118– 25. doi: 10.12786/bn.2014.7.2.118
- Boonsong P, Jaroenarpornwatana A, Boonhong J. Preliminary study of suprascapular nerve block (SSNB) in hemiplegic shoulder pain. J Med Assoc Thailand. (2009) 92:1669–74.
- Klç Z, Filiz MB, Çakr T, Toraman NF. Addition of suprascapular nerve block to a physical therapy program produces an extra benefit to adhesive capsulitis: a randomized controlled trial. *Am J Phys Med Rehab.* (2015) 94:912–20. doi: 10.1097/PHM.00000000000336

- Kang SS, Jung JW, Song CK, Yoon YJ, Shin KM. A new anterior approach for fluoroscopy-guided suprascapular nerve block - a preliminary report. *Korean J Pain*. (2012) 25:168–72. doi: 10.3344/kjp.2012.25.3.168
- Chan CW, Peng PWH. Suprascapular nerve block: a narrative review. *Reg Anesth Pain Med.* (2011) 36:358–73. doi: 10.1097/AAP.0b013e31822 04ec0
- Picelli A, Bonazza S, Lobba D, Parolini M, Martini A, Chemello E, et al. Suprascapular nerve block for the treatment of hemiplegic shoulder pain in patients with long-term chronic stroke: a pilot study. *Neurol Sci.* (2017) 38 (9):1697-1701. doi: 10.1007/s10072-017-3057-8
- Hodges PW, Smeets RJ. Interaction between pain, movement, and physical activity: short-term benefits, long-term consequences, and targets for treatment. *Clin J Pain*. (2015) 31:97–107. doi: 10.1097/AJP.000000000000008
- Sun, Y, Zhang, P, Liu, S, Li, H, Jiang, J, Chen, S, Chen, J. Intra-articular steroid injection for frozen shoulder: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. *Am J Sports Med.* (2017) 45:2171–9. doi: 10.1177/0363546516669944
- Parashar A, Goni V, Neradi D, Guled U, Rangasamy K, Batra YK. Comparing three modalities of treatment for frozen shoulder: a prospective, double-blinded, randomized control trial. *Indian J Orthop.* (2021) 55:449– 56. doi: 10.1007/s43465-020-00201-8
- Lin ML, Huang CT, Lin JG, Tsai SK. A comparison between the pain relief effect of electroacupuncture, regional never block and electroacupuncture plus regional never block in frozen shoulder. *Acta Anaesthesiol Sin.* (1994) 32:237–42.
- Aydin T, Sen E, Yardimci MY, Kesiktaş FN, Öneş K, Paker N. Efficacy of ultrasound-guided suprascapular nerve block treatment in patients with painful hemiplegic shoulder. *Neurol Sci.* (2019) 40:985–91. doi: 10.1007/s10072-019-03749-y
- Saglam G, Alisar DÇ. A comparison of the effectiveness of ultrasoundguided versus landmark-guided suprascapular nerve block in chronic shoulder pain: a prospective randomized study. *Pain Phys.* (2020) 23:581– 88. doi: 10.36076/ppj.2020.23.581

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Hou, Wang, Sun, Lou, Yu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.